Publications by authors named "Erica M Stringer-Reasor"

Claim this Profile
E
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, Roisin M Connolly, Brian L Burnette, Erica M Stringer-Reasor

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
Erica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, Ricardo Lastra, Gabrielle Baker

Breast Cancer Res Treat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky, Erica Michelle Stringer-Reasor

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Lior Z Braunstein, Melissa P Mitchell, Hanna Bandos, William M Sikov, Atif J Khan, Erica M Stringer-Reasor

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju, Erica M Stringer-Reasor

Breast Cancer Res Treat· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, Sofia F Garcia, Fei Shen, Erica M Stringer-Reasor

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

medRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between.
Hyo Sook Han, Praveen Vikas, Ricardo L B Costa, Nusrat Jahan, Ammanuel Taye, Erica M Stringer-Reasor

Am Soc Clin Oncol Educ Book· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li

Breast Cancer Res Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Erica M Stringer-Reasor

J Natl Compr Canc Netw· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in Breast Cancer Associated With African American Identity.
Erica M Stringer-Reasor, Ahmed Elkhanany, Katia Khoury, Melissa A Simon, Lisa A Newman

Am Soc Clin Oncol Educ Book· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Erica M Stringer-Reasor

J Natl Compr Canc Netw· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Erica M Stringer-Reasor, Jori E May, Eva Olariu, Valerie Caterinicchia, Yufeng Li

Breast Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Erica M Stringer-Reasor

J Natl Compr Canc Netw· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.
Rita Nanda, Erica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, Jean Gibson

Springerplus· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Erica M Stringer-Reasor, Gabrielle M Baker, Maxwell N Skor, Masha Kocherginsky, Ernst Lengyel

Gynecol Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis